查詢結果分析
相關文獻
- Enteral Indomethacin Therapy for Patent Ductus Arteriosus in Premature Infants: An Experience in One Medical Center in Southern Taiwan
- The Anesthetic Management of A Preterm Infant Weighing 500 Grams Undergoing Ligation of Patent Ductus Arteriosus--A Case Report
- 早產兒的開放性動脈導管
- Risk Factors of Pulmonary Hemorrhage in Very-Low-Birth-Weight Infants: A Two-year Retrospective Study
- 開放性動脈導管
- Ibuprofen與Indomethacin治療早產兒開放性動脈導管之比較
- Surgical Closure of Patent Ductus Arteriosus in Preterm Infants at Neonatal Intensive Care Unit
- Indomethacin與開放性動脈導管
- 開放性動脈導管(PDA)結紮後低血壓:腎上腺賀爾蒙的角色
- 在使用Indomethacin及Ibuprofen治療開放性動脈導管時的腸道進食
頁籤選單縮合
題名 | Enteral Indomethacin Therapy for Patent Ductus Arteriosus in Premature Infants: An Experience in One Medical Center in Southern Taiwan=南臺灣一醫學中心以口服Indomethacin治療早產兒開放性動脈導管之經驗 |
---|---|
作 者 | 林宜靜; 曾馨誼; 呂志忠; 徐仲豪; 戴任恭; 陳秀玲; 鐘育志; | 書刊名 | Clinical Neonatology |
卷期 | 14:2 2007.12[民96.12] |
頁次 | 頁69-74 |
分類號 | 417.5171 |
關鍵詞 | 早產兒; 開放性動脈導管; 口服Indomethacin; Patent ductus arteriosus; Enteral indomethacin; Preterm infants; |
語文 | 英文(English) |
英文摘要 | Introduction: Patent ductus arteriosus (PDA) is a common disease in preterm infants. Indomethacin has been used for closure of symptomatic PDA (sPDA). We report on enterally administered indomethacin treatment for preterm infants with sPDA to determine the closure rate, the potential risk factors associated with failed closure of sPDA and the prevalence of associated complications of oral indomethacin treatment. Materials and methods: This retrospective study included 58 infants with gestational ages of less than 37 weeks and birth weights of less than 2,400 g. The diagnosis of sPDA was confirmed by clinical symptoms and echocardiography. All the infants had received at least one course of enteral indomethacin treatment. The contents of an indomethacin capsule were mixed with water and made into a suspension. These infants received 0.2 mg/kg/dose every 12 hours 3 times enterally via a nasogastric tube. Ductal closure was confirmed by follow-up echocardiography between 12 and 36 hours after completion of a course of treatment. Side effects to indomethacin were monitored during treatment. Results: The total sPDA closure rate was 77.8% (n=45). The significant predictor of failed PDA closure after one course of indomethacin treatment was larger PDA size (p<0.05). Forty (62.5%) infants developed adverse side effects after indomethacin therapy. The most common side effect in our study was transient renal insufficiency (43.8%). Conclusion: For sPDA in prematurity, enteral indomethacin is still an acceptable alternative if the intravenous form is not available. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。